共 9 条
[1]
[2]
[3]
[4]
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised; placebo-controlled; double-blind study[J] Giancarlo Agnelli;Gualberto Gussoni;Carlo Bianchini;Melina Verso;Mario Mandalà;Luigi Cavanna;Sandro Barni;Roberto Labianca;Franco Buzzi;Giovanni Scambia;Rodolfo Passalacqua;Sergio Ricci;Giampietro Gasparini;Vito Lorusso;Erminio Bonizzoni;Maurizio Tonato Lancet Oncology 2009,
[5]
Risk of venous thromboembolism in lung cancer[J] Margot ET Tesselaar;Susanne Osanto Current Opinion in Pulmonary Medicine 2007,
[6]
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J] A. A.KHORANA;C. W.FRANCIS;E.CULAKOVA;N. M.KUDERER;G. H.LYMAN Journal of Thrombosis and Haemostasis 2007,
[7]
Use of D-dimer to aid in excluding deep venous thrombosis in ambulatory patients[J] Scott Diamond;Robert Goldbweber;Steven Katz The American Journal of Surgery 2005,
[8]
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma[J] J. W.Blom;S.Osanto;F. R.Rosendaal Journal of Thrombosis and Haemostasis 2004,
[9]
A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer[J] M.Altinbas;H. S.Coskun;O.Er;M.Ozkan;B.Eser;A.Unal;M.Cetin;S.Soyuer Journal of Thrombosis and Haemostasis 2004,

